TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
TG Therapeutics (NASDAQ: TGTX) announced that Michael S. Weiss, Chairman and CEO, will present at the 44th Annual J.P.
Rhea-AI Summary
TG Therapeutics (NASDAQ: TGTX) announced that Michael S. Weiss, Chairman and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 13, 2026 at 1:30 PM PST. A live webcast will be available on the company’s Events page in the Investors & Media section at http://ir.tgtherapeutics.com/events, and a replay will be posted on TG’s website after the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – TGTX
On Jan 7, the day this news came out, TGTX closed 3.16% above the previous close.
Data tracked by StockTitan Argus for the Jan 7 session.
Key Figures
- JPM presentation time
- 1:30 PM PST, Jan 13, 2026
- Scheduled conference presentation
- Q3 2025 revenue
- $161.7M
- Third quarter 2025 total revenue
- Q3 2025 BRIUMVI U.S. revenue
- $152.9M
- BRIUMVI U.S. net revenue in Q3 2025
- Q3 2025 net income
- $390.9M
- Net income in Q3 2025 10‑Q
- Diluted EPS
- $2.43
- Q3 2025 diluted earnings per share
- Cash & investments
- $178.3M
- Cash, cash equivalents and investment securities as of Sep 30, 2025
- 2025 YTD revenue
- $423.7M
- Total revenue for first nine months of 2025
- Shares outstanding
- 158,759,451
- Common shares outstanding as of Oct 31, 2025
Historical Context
-
Announcement of Evercore healthcare conference fireside chat and webcast access.
-
Inclusion on Deloitte 2025 Technology Fast 500 list driven by BRIUMVI growth.
-
Participation in TD Cowen Immunology & Inflammation Summit with investor webcast.
-
Q3 2025 results with strong BRIUMVI revenue and raised full‑year guidance.
-
Notice of Q3 2025 earnings call and business outlook webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Presentation scheduled for Tuesday, January 13, 2026, at 1:30 PM PST
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Tuesday, January 13, 2026, at 1:30 PM PST.
A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TG’s website following the event.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.